{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:02:17Z","timestamp":1778605337254,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100010434","name":"\u201cla Caixa\u201d Foundation","doi-asserted-by":"publisher","award":["LCF\/BQ\/EU21\/11890141"],"award-info":[{"award-number":["LCF\/BQ\/EU21\/11890141"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lexicon Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10557-023-07469-6","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T05:01:45Z","timestamp":1686805305000},"page":"155-164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes"],"prefix":"10.1007","volume":"39","author":[{"given":"Maeve Soto","family":"P\u00e9rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Rodr\u00edguez-Capit\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Antonio","family":"Requena-Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos G.","family":"Santos-Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Urooj Zafar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gin\u00e9s","family":"Escolar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumeet","family":"Mitter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna P.","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Icilma","family":"Fergus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Atallah-Lajam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Abascal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Lala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah","family":"Moss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stamatios","family":"Lerakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Fuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6780-8771","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"Badimon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"7469_CR1","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ejhf.483","volume":"18","author":"EES van Riet","year":"2016","unstructured":"van Riet EES, Hoes AW, Wagenaar KP, Limburg A, Landman MAJ, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time A systematic review. Eur J Heart Fail. 2016;18:242\u201352.","journal-title":"Eur J Heart Fail"},{"key":"7469_CR2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"7469_CR3","first-page":"e876","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e876\u201394.","journal-title":"Circulation"},{"key":"7469_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3390\/cells9010242","volume":"9","author":"SJ Simmonds","year":"2020","unstructured":"Simmonds SJ, Cuijpers I, Heymans S, Jones EAV. Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding. Cells. 2020;9:242.","journal-title":"Cells"},{"key":"7469_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"7469_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/jcm12010379","volume":"12","author":"L Pistelli","year":"2023","unstructured":"Pistelli L, Parisi F, Correale M, et al. Gliflozins: from antidiabetic drugs to cornerstone in heart failure therapy-a boost to their utilization and multidisciplinary approach in the management of heart failure. J Clin Med. 2023;12:379.","journal-title":"J Clin Med"},{"key":"7469_CR7","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","volume":"145","author":"CW Tsao","year":"2022","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022;145:e153-639.","journal-title":"Circulation"},{"key":"7469_CR8","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1161\/CIRCULATIONAHA.121.056657","volume":"144","author":"M Packer","year":"2021","unstructured":"Packer M, Zannad F, Anker SD. Heart failure and a preserved ejection fraction: a side-by-side examination of the PARAGON-HF and EMPEROR-Preserved trials. Circulation. 2021;144:1193\u20135.","journal-title":"Circulation"},{"key":"7469_CR9","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1093\/eurheartj\/ehac417","volume":"43","author":"B Pitt","year":"2022","unstructured":"Pitt B, Bhatt DL, Metra M. Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure? Eur Heart J. 2022;43:4754\u20137.","journal-title":"Eur Heart J"},{"key":"7469_CR10","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.2147\/DDDT.S114932","volume":"11","author":"F Cinti","year":"2017","unstructured":"Cinti F, Moffa S, Impronta F, et al. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther. 2017;11:2905\u201319.","journal-title":"Drug Des Devel Ther"},{"key":"7469_CR11","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451\u201361.","journal-title":"N Engl J Med"},{"key":"7469_CR12","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089\u201398.","journal-title":"N Engl J Med"},{"key":"7469_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","volume":"19","author":"G Savarese","year":"2022","unstructured":"Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19:100\u201316.","journal-title":"Nat Rev Cardiol"},{"key":"7469_CR14","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1093\/eurheartj\/ehaa158","volume":"41","author":"CSP Lam","year":"2020","unstructured":"Lam CSP, Voors AA, Piotr P, McMurray JJV, Solomon SD. Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. Eur Heart J. 2020;41:2353\u20135.","journal-title":"Eur Heart J"},{"key":"7469_CR15","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1161\/CIRCULATIONAHA.119.045561","volume":"141","author":"M Packer","year":"2020","unstructured":"Packer M. Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance. Circulation. 2020;141:2095\u2013105.","journal-title":"Circulation"},{"key":"7469_CR16","doi-asserted-by":"publisher","unstructured":"Packer M. SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism. Nat Rev Cardiol. 2023. https:\/\/doi.org\/10.1038\/s41569-022-00824-4.","DOI":"10.1038\/s41569-022-00824-4"},{"key":"7469_CR17","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.115.012427","volume":"133","author":"CG Santos-Gallego","year":"2016","unstructured":"Santos-Gallego CG, Vahl TP, Goliasch G, et al. Sphingosine-1-phosphate receptor agonist fingolimod increases myocardial salvage and decreases adverse postinfarction left ventricular remodeling in a porcine model of ischemia\/reperfusion. Circulation. 2016;133:954\u201366.","journal-title":"Circulation"},{"issue":"10","key":"7469_CR18","doi-asserted-by":"publisher","first-page":"H1478","DOI":"10.1152\/ajpheart.00797.2013","volume":"307","author":"K Ishikawa","year":"2014","unstructured":"Ishikawa K, Aguero J, Tilemann L, et al. Characterizing preclinical models of ischemic heart failure: differences between LAD and LCx infarctions. Am J Physiol Heart Circ Physiol. 2014;307(10):H1478\u201386.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"15","key":"7469_CR19","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"7469_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1161\/CIRCULATIONAHA.122.060805","volume":"146","author":"CG Santos-Gallego","year":"2022","unstructured":"Santos-Gallego CG, Mayr M, Badimon J. SGLT2 inhibitors in heart failure: targeted metabolomics and energetic metabolism. Circulation. 2022;146(11):819\u201321.","journal-title":"Circulation"},{"issue":"21","key":"7469_CR21","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1161\/CIRCULATIONAHA.121.054858","volume":"144","author":"MK Burrage","year":"2021","unstructured":"Burrage MK, Hundertmark M, Valkovi\u010d L, et al. Energetic basis for exercise-induced pulmonary congestion in heart failure with preserved ejection fraction. Circulation. 2021;144(21):1664\u201378.","journal-title":"Circulation"},{"issue":"2","key":"7469_CR22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","volume":"14","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis\/stiffness in nondiabetic heart failure: a multimodality study. JACC Cardiovasc Imaging. 2021;14(2):393\u2013407.","journal-title":"JACC Cardiovasc Imaging"},{"key":"7469_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","volume":"77","author":"CG Santos-Gallego","year":"2021","unstructured":"Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77:243\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"7469_CR24","doi-asserted-by":"publisher","first-page":"102417","DOI":"10.1016\/j.dsx.2022.102417","volume":"16","author":"JA Requena-Ib\u00e1\u00f1ez","year":"2022","unstructured":"Requena-Ib\u00e1\u00f1ez JA, Santos-Gallego CG, Rodriguez-Cordero A, et al. Empagliflozin improves quality of life in nondiabetic HFrEF patients Sub-analysis of the EMPATROPISM trial. Diabetes Metab Syndr. 2022;16(2):102417.","journal-title":"Diabetes Metab Syndr."},{"key":"7469_CR25","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","volume":"9","author":"JA Requena-Ib\u00e1\u00f1ez","year":"2021","unstructured":"Requena-Ib\u00e1\u00f1ez JA, Santos-Gallego CG, Rodriguez-Cordero A, et al. Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM Study. JACC Heart Fail. 2021;9:578\u201389.","journal-title":"JACC Heart Fail"},{"key":"7469_CR26","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/ejhf.2337","volume":"23","author":"NR Pugliese","year":"2021","unstructured":"Pugliese NR, Paneni F, Mazzola M, et al. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. Eur J Heart Fail. 2021;23:1858\u201371.","journal-title":"Eur J Heart Fail"},{"key":"7469_CR27","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1002\/ejhf.2363","volume":"23","author":"J Tromp","year":"2021","unstructured":"Tromp J, Packer M, Lam CS. The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal. Eur J Heart Fail. 2021;23:1872\u20134.","journal-title":"Eur J Heart Fail"},{"key":"7469_CR28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jchf.2020.06.003","volume":"8","author":"TM Gorter","year":"2020","unstructured":"Gorter TM, van Woerden G, Rienstra M, et al. Epicardial adipose tissue and invasive hemodynamics in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8:667\u201376.","journal-title":"JACC Heart Fail"},{"key":"7469_CR29","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jchf.2020.04.016","volume":"8","author":"KE Koepp","year":"2020","unstructured":"Koepp KE, Obokata M, Reddy YNV, Olson TP, Borlaug BA. Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8:657\u201366.","journal-title":"JACC Heart Fail"},{"key":"7469_CR30","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","volume":"71","author":"M Packer","year":"2018","unstructured":"Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol. 2018;71:2360\u201372.","journal-title":"J Am Coll Cardiol"},{"key":"7469_CR31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jchf.2021.05.019","volume":"9","author":"M Packer","year":"2021","unstructured":"Packer M. Differential pathophysiological mechanisms in heart failure with a reduced or preserved ejection fraction in diabetes. JACC Heart Fail. 2021;9:535\u201349.","journal-title":"JACC Heart Fail"},{"key":"7469_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","volume":"243","author":"A Di Franco","year":"2017","unstructured":"Di Franco A, Cantini G, Tani A, et al. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target. Int J Cardiol. 2017;243:86\u201390.","journal-title":"Int J Cardiol"},{"key":"7469_CR33","doi-asserted-by":"publisher","first-page":"9852","DOI":"10.3390\/ijms22189852","volume":"22","author":"AA Sayour","year":"2021","unstructured":"Sayour AA, Ruppert M, Ol\u00e1h A, et al. Effects of SGLT2 inhibitors beyond glycemic control-focus on myocardial SGLT1. Int J Mol Sci. 2021;22:9852.","journal-title":"Int J Mol Sci"},{"key":"7469_CR34","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.jacc.2018.07.061","volume":"72","author":"SB Seidelmann","year":"2018","unstructured":"Seidelmann SB, Feofanova E, Yu B, et al. Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk. J Am Coll Cardiol. 2018;72:1763\u201373.","journal-title":"J Am Coll Cardiol"},{"key":"7469_CR35","doi-asserted-by":"publisher","first-page":"700366","DOI":"10.3389\/fphar.2021.700366","volume":"12","author":"H Lin","year":"2021","unstructured":"Lin H, Guan L, Meng L, Uzui H, Guo H. SGLT1 knockdown attenuates cardiac fibroblast activation in diabetic cardiac fibrosis. Front Pharmacol. 2021;12:700366.","journal-title":"Front Pharmacol"},{"key":"7469_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117\u201328.","journal-title":"N Engl J Med"},{"key":"7469_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384:129\u201339.","journal-title":"N Engl J Med"},{"key":"7469_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-021-01272-z","volume":"20","author":"C Zheng","year":"2021","unstructured":"Zheng C, Lin M, Chen Y, Xu H, Yan L, Dai H. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials. Cardiovasc Diabetol. 2021;20:83.","journal-title":"Cardiovasc Diabetol"},{"key":"7469_CR39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-019-0812-6","volume":"18","author":"RE Gilbert","year":"2019","unstructured":"Gilbert RE, Connelly KA. Reduction in the incidence of myocardial infarction with sodium-glucose linked cotransporter-2 inhibitors: evident and plausible. Cardiovasc Diabetol. 2019;18:6.","journal-title":"Cardiovasc Diabetol"},{"key":"7469_CR40","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6:148\u201358.","journal-title":"JAMA Cardiol"},{"key":"7469_CR41","doi-asserted-by":"publisher","first-page":"106049","DOI":"10.1016\/j.phrs.2021.106049","volume":"176","author":"Y Li","year":"2022","unstructured":"Li Y, Xu G. Sodium glucose cotransporter 1 (SGLT1) inhibitors in cardiovascular protection: Mechanism progresses and challenges. Pharmacol Res. 2022;176:106049.","journal-title":"Pharmacol Res"},{"key":"7469_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-019-0828-y","volume":"18","author":"CMA Cefalo","year":"2019","unstructured":"Cefalo CMA, Cinti F, Moffa S, et al. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol. 2019;18:20.","journal-title":"Cardiovasc Diabetol"},{"key":"7469_CR43","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jacc.2012.09.066","volume":"61","author":"S Rekhraj","year":"2013","unstructured":"Rekhraj S, Gandy SJ, Szwejkowski BR, et al. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 2013;61:926\u201332.","journal-title":"J Am Coll Cardiol"},{"key":"7469_CR44","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891\u2013975.","journal-title":"Eur J Heart Fail."},{"key":"7469_CR45","unstructured":"Andreini D, Conte E, Mushtaq S, et al. Comprehensive evaluation of left ventricle dysfunction by a new computed tomography scanner: the E-PLURIBUS Study. JACC Cardiovasc Imaging. 2022;S1936\u2013878X(22)00490\u20139."},{"key":"7469_CR46","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.mri.2021.11.004","volume":"86","author":"JA Requena-Ib\u00e1\u00f1ez","year":"2022","unstructured":"Requena-Ib\u00e1\u00f1ez JA, Santos-Gallego CG, Rodriguez Cordero AJ, et al. Not only how much, but also how to, when measuring epicardial adipose tissue. Magn Reson Imaging. 2022;86:149\u201351.","journal-title":"Magn Reson Imaging"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07469-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07469-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07469-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T09:59:47Z","timestamp":1738835987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07469-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["7469"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07469-6","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"9 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants are in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The protocol was approved by the Mount Sinai Institutional Review Board (GCO 22\u20130574) and received IND 165123 by the FDA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent is obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"This study has been funded by an Investigator-Initiated Grant to Dr. Badimon by Lexicon Pharmaceuticals, Inc.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}